Another potent intervention is the use of bispecific antibodies with a CD20 or CD19 binding portion and a second portion specific to T lymphocytes (CD3) to promote the attachment of T lymphocytes to target cells, such as tumor B cells, increasing cytotoxicity and the activation of anti-tumor response [121]. The gene discussed is CD19; the disease is neoplasm.